Our technology platform utilizes fluid dynamics (specifically Taylor-Couette-Poiseuille [TCP] flow) to generate therapeutics. The goal of this unique application of physics is to produce drugs that protect cells from acute injury and correct the foundational imbalances that contribute to the progressive nature of many neurological conditions, specifically mitochondrial dysfunction and inflammation. Because these imbalances underlie many different diseases, we believe our platform will have clinical application beyond our initial neurological focus, such as in reperfusion injuries like acute myocardial infarction.